Novocure Ltd. Stock

$11.70

5.87% yesterday

Nasdaq, Aug 25, 10:14 pm CET

ISIN

JE00BYSS4X48

Symbol

NVCR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Overview Dividends Analysts Charts News Strategies

Novocure Ltd. Stock price

$11.70

-68.32 85.38% 5Y

Nasdaq, Closing price Mon, Aug 25 2025

-0.73 5.87%

ISIN

JE00BYSS4X48

Symbol

NVCR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Key metrics

Basic

Market capitalization

$1.4b

Enterprise Value

Net debt

Cash

Shares outstanding

Valuation (TTM | estimate)

P/E

negative | negative

P/S

2.2 | 2.2

EV/Sales

- | -

EV/FCF

P/B

Financial Health

Equity Ratio

29.0%

Return on Equity

-46.8%

ROCE

ROIC

Debt/Equity

Financials (TTM | estimate)

Revenue

$630.2m | $645.6m

EBITDA

$-156.9m | $-58.1m

EBIT

$-169.2m | $-176.8m

Net Income

$-171.0m | -

Free Cash Flow

$-80.4m

Growth (TTM | estimate)

Revenue

14.6% | 6.7%

EBITDA

8.7% | 63.1%

EBIT

7.6% | -4.9%

Net Income

-1.3% | -

Free Cash Flow

23.0%

EPS

$-1.5

FCF per Share

Short interest

7.4%

Employees

Rev per Employee

$410.0k

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Get Started for Free Today

Novocure Ltd. Stock Analysis

Unlock Scores for Free

??

14 Analysts have issued a Novocure Ltd. forecast:

10x Buy

71%

4x Hold

29%

More details on Analyst Estimates Including Price Targets

14 Analysts have issued a Novocure Ltd. forecast:

Buy

71%

Hold

29%

Analyst Estimates with Stock Price Targets

Financial data from Novocure Ltd.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	630 630	15% 15% 100%
- Direct Costs	148 148	11% 11% 23%
Gross Profit	483 483	16% 16% 77%
- Selling and Administrative Expenses	439 439	14% 14% 70%
- Research and Development Expense	213 213	1% 1% 34%
EBITDA	-157 -157	9% 9% -25%
- Depreciation and Amortization	12 12	10% 10% 2%
EBIT (Operating Income) EBIT	-169 -169	8% 8% -27%
Net Profit	-171 -171	1% 1% -27%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Novocure Ltd. Stock News

Neutral

Business Wire

●

about 12 hours ago

Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Spain's Ministry of Health has made Tumor Treating Fields (TTFields) therapy available through the Spanish National Health System (SNS) for the treatment of adult patients with newly diagnosed glioblastoma. “Glioblastoma is one of the most common and aggressive forms of primary brain cancer with few treatment optio...

Neutral

Business Wire

●

5 days ago

Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer. This submission is supported by the PANOVA-3 trial, which evaluated the use of TTFields therapy concomitantly with gemci...

Positive

Seeking Alpha

●

27 days ago

NovoCure's Wearable Oncology Edge And Compelling Valuation

NVCR focuses on Tumor Treating Fields wearables for GBM, mesothelioma, and NSCLC. These are its main recurring revenue verticals. So far, its wearables have shown favorable safety profiles, and suggest they should be a net benefit across other oncology niches. NVCR's late‑stage PANOVA‑3 and METIS trials could continue growing their markets. Currently, management is targeting more PMA filings la...

More Novocure Ltd. News

Company Profile

NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Head office	Jersey
CEO	Ms. Cordova
Employees	1,488
Founded	2000
Website	www.novocure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now